Holen Sie sich die Stockscreener-App
5.29
5.59%
0.28
Handel nachbörslich:
5.29
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan
New breast cancer test detects residual disease beyond standard scans - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research - MarketBeat
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares - MarketBeat
Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock - MarketBeat
S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock - MarketBeat
Myriad Genetics Insider Bought Shares Worth $494,722, According to a Recent SEC Filing - marketscreener.com
Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 60% Upside Potential Amidst Financial Challenges - DirectorsTalk Interviews
How Myriad Genetics Inc. (MYGN) Affects Rotational Strategy Timing - Stock Traders Daily
GXD-Bio Appeals Genetic Tester IP Loss Against Myriad - Law360
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Inc files for mixed shelf of up to $200 millionSEC filing - marketscreener.com
Myriad Genetics Inc Files For Mixed Shelf Of Up To $200 MillionSEC Filing - TradingView
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead By Investing.com - Investing.com South Africa
Cancer, prenatal and mental health tests anchor Myriad (MYGN) 2025 plan - Stock Titan
MYGN: UBS Maintains Neutral Rating, Lowers Price Target to $6.00 - GuruFocus
MYGN: Wells Fargo Lowers Price Target for Myriad Genetics | MYGN Stock News - GuruFocus
Why Myriad Genetics (MYGN) Stock Is Trading Up Today - Finviz
Myriad Genetics (MYGN) Unveils New Data on Cancer Diagnostics at ASCO-GU 2026 - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating - marketscreener.com
Wells Fargo & Company Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00 - MarketBeat
Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth - Seeking Alpha
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead - Investing.com Nigeria
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests - Bitget
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests - The Manila Times
Myriad cancer tests at ASCO-GU challenge prostate risk rules - Stock Titan
Myriad Genetics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down - TradingView
Myriad Genetics (MYGN) Stock Surges on Earnings Beat and Revenue Goals - GuruFocus
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y (MYGN:NASDAQ) - Seeking Alpha
MYGN Financials: Income Statement, Balance Sheet & Cash Flow | Myriad Genetics - Stock Titan
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Sur - GuruFocus
Myriad Genetics Reports Strong Q4 2025 Earnings and Growth Outlook - Intellectia AI
Here's what key metrics tell us about Myriad (MYGN) Q4 earnings - MSN
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings - Yahoo Finance
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates - Nasdaq
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript - The Globe and Mail
Myriad Genetics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Myriad Genetics Q4 2025 beats EPS forecast, stock rises - Investing.com Australia
Myriad: Q4 Earnings Snapshot - kens5.com
Myriad: Fourth Quarter Financial Highlights - Bitget
Myriad Genetics Q4 Loss Narrows - Nasdaq
MYGN Forecasts Near Breakeven EBITDA in Q1 2026 - GuruFocus
Myriad Genetics Q4 Earnings Exceed Expectations - Intellectia AI
Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results - MarketBeat
Myriad Genetics (MYGN) Reports Strong Q4 and Announces Key Devel - GuruFocus
Myriad Genetics's (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% - Finviz
Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% - Yahoo Finance
Myriad Genetics Earnings Report: Q4 Overview - Benzinga
Myriad Genetics (NASDAQ: MYGN) posts Q4 2025 loss, reiterates 2026 outlook - Stock Titan
New cancer and prenatal tests aimed to drive growth at Myriad Genetics - Stock Titan
iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know - Finviz
Myriad Genetics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:MYGN) 2026-02-23 - Seeking Alpha
Aug Summary: Does Myriad Genetics Inc have pricing powerWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Aberdeen Group plc Boosts Stock Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics, Inc. (MYGN): Investor Outlook on a Healthcare Innovator with 85% Upside Potential - DirectorsTalk Interviews
Myriad Genetics Q4 2025 earnings preview - MSN
0.90%
3.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):